|
Market Cap | 15.09B | EPS (ttm) | 12.35 |
P/E | 14.10 | EPS this Y | 4.74% |
Forward P/E | 10.92 | EPS next Y | 5.62% |
PEG | 1.83 | EPS past 5Y | 21.79% |
P/S | 1.56 | EPS next 5Y | 7.70% |
P/B | 2.89 | EPS Q/Q | -18.38% |
Dividend | 1.38% | Sales Q/Q | -1.33% |
Insider Own | 1.04% | Inst Own | 93.48% |
Insider Trans | -4.81% | Inst Trans | -1.89% |
Short Float | 1.85% | Earnings | Apr 24/b |
Analyst Recom | 2.24 | Target Price | 184.22 |
Avg Volume | 631.94K | 52W Range | 105.56 - 183.32 |
|
|
|
Owens Corning engages in the development, manufacture, and marketing of insulation, roofing, and fiberglass composites. It operates through the following segments: Composites, Insulation, and Roofing. The Composites segment manufactures, fabricates, and sells glass reinforcements in the form of fiber, and includes vertically integrated downstream activities. The Insulation segment provides insulating products which help customers conserve energy, provide improved acoustical performance, and offer convenience of installation and use. The Roofing segment offers laminate and strip asphalt roofing shingles and other products including oxidized asphalt and roofing accessories. The company was founded on October 31, 1938, and is headquartered in Toledo, OH. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Sandri Marcio A | President, Composites | May 24 '24 | Sale | 178.00 | 9,697 | 1,726,066 | 62,895 | May 29 04:11 PM | Del Monaco Nicolas | President, Insulation | May 21 '24 | Sale | 176.47 | 3,423 | 604,057 | 11,381 | May 23 04:54 PM | Mendez-Andino Jose | EVP, Chief R&D Officer | Mar 15 '24 | Sale | 156.72 | 2,833 | 443,988 | 14,814 | Mar 19 04:18 PM | Russell Paula | EVP, Chief HR Officer | Mar 14 '24 | Sale | 162.00 | 3,765 | 609,930 | 20,419 | Mar 15 04:19 PM | Smith Gunner | President, Roofing | Feb 14 '24 | Sale | 148.99 | 7,442 | 1,108,784 | 36,140 | Feb 15 04:29 PM |
|
|
|
|
Market Cap | 113.83B | EPS (ttm) | 15.41 |
P/E | 28.62 | EPS this Y | 11.15% |
Forward P/E | 24.27 | EPS next Y | 7.35% |
PEG | 2.28 | EPS past 5Y | 11.42% |
P/S | 11.19 | EPS next 5Y | 12.53% |
P/B | 6.14 | EPS Q/Q | 56.65% |
Dividend | - | Sales Q/Q | 14.21% |
Insider Own | 0.27% | Inst Own | 92.79% |
Insider Trans | -17.30% | Inst Trans | 1.21% |
Short Float | 1.46% | Earnings | May 06/a |
Analyst Recom | 1.94 | Target Price | 466.23 |
Avg Volume | 1.06M | 52W Range | 320.01 - 457.66 |
|
|
|
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Kewalramani Reshma | CEO & President | May 24 '24 | Option Exercise | 187.53 | 1,565 | 293,484 | 122,939 | May 29 04:08 PM | Kewalramani Reshma | CEO & President | May 24 '24 | Sale | 457.00 | 1,565 | 715,205 | 121,374 | May 29 04:08 PM | SACHS BRUCE I | Director | May 22 '24 | Option Exercise | 93.51 | 7,073 | 661,396 | 47,073 | May 24 04:13 PM | SACHS BRUCE I | Director | May 22 '24 | Sale | 448.00 | 7,073 | 3,168,704 | 40,000 | May 24 04:13 PM | Kewalramani Reshma | CEO & President | May 20 '24 | Sale | 447.00 | 15,202 | 6,795,294 | 121,374 | May 22 04:21 PM |
|
|
|
|
Market Cap | 318.95M | EPS (ttm) | -0.57 |
P/E | - | EPS this Y | 42.62% |
Forward P/E | 10.46 | EPS next Y | 166.04% |
PEG | - | EPS past 5Y | 6.34% |
P/S | 0.32 | EPS next 5Y | - |
P/B | 0.99 | EPS Q/Q | 24.32% |
Dividend | - | Sales Q/Q | 13.80% |
Insider Own | 64.62% | Inst Own | 12.95% |
Insider Trans | -1.39% | Inst Trans | 0.60% |
Short Float | 2.55% | Earnings | May 07/a |
Analyst Recom | 3.20 | Target Price | 2.45 |
Avg Volume | 404.77K | 52W Range | 1.14 - 3.71 |
|
|
|
loanDepot, Inc. engages in the business of originating, financing, selling, and servicing residential mortgage loans, title, escrow, and settlement services for mortgage loan transactions. It also offers a variety of loan products and in-house servicing platforms. The company was founded by Anthony Hsieh in December 2009 and is headquartered in Irvine, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Hsieh Anthony Li | Director | May 28 '24 | Sale | 1.86 | 50,000 | 93,025 | 3,006,605 | May 29 04:06 PM | Hsieh Anthony Li | Director | May 24 '24 | Sale | 1.98 | 76,210 | 150,515 | 3,056,605 | May 29 04:06 PM | Hsieh Anthony Li | Director | May 23 '24 | Sale | 2.02 | 122,808 | 248,563 | 3,132,815 | May 23 06:52 PM | Hsieh Anthony Li | Director | May 22 '24 | Sale | 2.03 | 38,504 | 78,048 | 3,255,623 | May 23 06:52 PM | Hsieh Anthony Li | Director | May 21 '24 | Sale | 2.05 | 123,280 | 252,416 | 3,294,127 | May 22 04:18 PM |
|
|
| |
|
Market Cap | 35.81B | EPS (ttm) | 3.43 |
P/E | 22.90 | EPS this Y | 8.86% |
Forward P/E | 16.45 | EPS next Y | 11.49% |
PEG | 1.99 | EPS past 5Y | -2.54% |
P/S | 1.84 | EPS next 5Y | 11.50% |
P/B | 4.83 | EPS Q/Q | 97.00% |
Dividend | 0.08% | Sales Q/Q | -1.21% |
Insider Own | 7.03% | Inst Own | 75.28% |
Insider Trans | -0.28% | Inst Trans | - |
Short Float | 2.44% | Earnings | Apr 30/b |
Analyst Recom | 1.75 | Target Price | 93.61 |
Avg Volume | 3.04M | 52W Range | 62.35 - 94.50 |
|
|
|
GE Healthcare Technologies, Inc. engages in the development and manufacturing of medical technology, pharmaceutical diagnostics, and digital solutions. It operates through the following segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment provides scanning devices, clinical applications, service capabilities and digital solutions. The Ultrasound segment offers screening, diagnosis, treatment, and monitoring of certain diseases. The Patient Care Solutions segment specializes in providing medical devices, consumables, services, and digital solutions. The Pharmaceutical Diagnostics segment supplies diagnostic agents to the global radiology and nuclear medicine community. The company was founded on May 16, 2022 and is headquartered in Chicago, IL. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Kass-Hout Taha | Chief Technology Officer | May 28 '24 | Sale | 78.70 | 3,300 | 259,710 | 67,300 | May 29 04:05 PM | Makela Jan | CEO, Imaging | May 15 '24 | Option Exercise | 74.35 | 66,955 | 4,978,229 | 130,303 | May 15 07:15 PM | Makela Jan | CEO, Imaging | May 15 '24 | Sale | 81.54 | 66,955 | 5,459,511 | 63,348 | May 15 07:15 PM | Makela Jan | CEO, Imaging | May 13 '24 | Option Exercise | 63.51 | 20,227 | 1,284,617 | 83,575 | May 15 07:15 PM | Makela Jan | CEO, Imaging | May 13 '24 | Sale | 81.57 | 20,227 | 1,649,916 | 63,348 | May 15 07:15 PM |
|
|
|
|
Market Cap | 3.18B | EPS (ttm) | -1.48 |
P/E | - | EPS this Y | 12.21% |
Forward P/E | 8.32 | EPS next Y | 14.49% |
PEG | - | EPS past 5Y | -39.50% |
P/S | 1.41 | EPS next 5Y | - |
P/B | - | EPS Q/Q | 46.17% |
Dividend | - | Sales Q/Q | 9.47% |
Insider Own | 12.86% | Inst Own | 88.78% |
Insider Trans | -4.18% | Inst Trans | 0.70% |
Short Float | 5.52% | Earnings | May 07/a |
Analyst Recom | 2.22 | Target Price | 39.94 |
Avg Volume | 1.01M | 52W Range | 25.08 - 43.28 |
|
|
|
RingCentral, Inc. engages in the provision of global enterprise cloud communications and collaboration solutions. The firm's solutions provide a single user identity across multiple locations and devices, including smartphones, tablets, PCs and desk phones, and allows for communication across multiple modes, including high-definition voice, video, SMS, messaging and collaboration, conferencing, online meetings and fax. It sells its products under the RingCentral Professional, RingCentral Glip, and RingCentral Fax brands. The company was founded by Vlad Vendrow and Vladimir Shmunis in 1999 and is headquartered in Belmont, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Parekh Sonalee Elizabeth | CHIEF FINANCIAL OFFICER | May 28 '24 | Sale | 34.85 | 8,478 | 295,433 | 388,919 | May 29 04:05 PM | Shmunis Vladimir | CEO and Chairman | May 22 '24 | Sale | 35.52 | 32,013 | 1,137,237 | 635,969 | May 23 04:05 PM | Marlow John H | SVP, CAO & GENERAL COUNSEL | May 22 '24 | Sale | 35.52 | 14,228 | 505,389 | 411,040 | May 23 04:05 PM | Shmunis Vladimir | CEO and Chairman | May 21 '24 | Sale | 35.92 | 66,530 | 2,389,817 | 667,982 | May 23 04:05 PM | Marlow John H | SVP, CAO & GENERAL COUNSEL | May 21 '24 | Sale | 35.92 | 19,497 | 700,334 | 425,268 | May 23 04:05 PM |
|
|
| |
|
Market Cap | 93.07B | EPS (ttm) | 7.46 |
P/E | 19.64 | EPS this Y | -37.56% |
Forward P/E | 28.65 | EPS next Y | 13.20% |
PEG | 1.06 | EPS past 5Y | - |
P/S | 9.09 | EPS next 5Y | 18.60% |
P/B | 11.81 | EPS Q/Q | 132.07% |
Dividend | - | Sales Q/Q | 17.82% |
Insider Own | 32.33% | Inst Own | 53.07% |
Insider Trans | -1.55% | Inst Trans | -1.19% |
Short Float | 3.11% | Earnings | May 08/a |
Analyst Recom | 2.76 | Target Price | 151.26 |
Avg Volume | 4.19M | 52W Range | 103.74 - 170.10 |
|
|
|
Airbnb, Inc. engages in the management and operation of an online marketplace. Its marketplace model connects hosts and guests online or through mobile devices to book spaces. The company was founded by Brian Chesky, Nathan Blecharczyk and Joseph Gebbia in 2007 and is headquartered in San Francisco, CA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
BALOGH ARISTOTLE N | Chief Technology Officer | May 28 '24 | Sale | 146.00 | 600 | 87,600 | 211,774 | May 29 04:05 PM | BALOGH ARISTOTLE N | Chief Technology Officer | May 21 '24 | Sale | 145.71 | 600 | 87,426 | 212,374 | May 22 05:26 PM | BALOGH ARISTOTLE N | Chief Technology Officer | May 14 '24 | Sale | 149.40 | 600 | 89,640 | 219,304 | May 16 04:05 PM | BALOGH ARISTOTLE N | Chief Technology Officer | May 07 '24 | Sale | 162.00 | 600 | 97,200 | 219,904 | May 09 04:05 PM | BALOGH ARISTOTLE N | Chief Technology Officer | Apr 30 '24 | Sale | 161.02 | 600 | 96,612 | 220,504 | May 02 04:05 PM |
|
|
|
|
Market Cap | 5.06B | EPS (ttm) | -0.58 |
P/E | - | EPS this Y | 37.69% |
Forward P/E | 31.81 | EPS next Y | 21.38% |
PEG | - | EPS past 5Y | 13.22% |
P/S | 6.12 | EPS next 5Y | 44.70% |
P/B | 14.17 | EPS Q/Q | 44.51% |
Dividend | - | Sales Q/Q | 14.36% |
Insider Own | 1.71% | Inst Own | 91.89% |
Insider Trans | -20.77% | Inst Trans | 0.77% |
Short Float | 3.03% | Earnings | May 01/a |
Analyst Recom | 1.65 | Target Price | 58.58 |
Avg Volume | 813.24K | 52W Range | 33.85 - 53.50 |
|
|
|
Tenable Holdings, Inc. engages in the development of security software solutions. It offers Cyber Exposure which is a discipline for managing and measuring cybersecurity risk in the digital era. Its products include tenable.io, tenable.sc, tenable.ot, and nessus professional. The firm delivers solutions in the field of application security, cloud security, compliance, energy, finance, healthcare, and retail. The company was founded by John C. Huffard, Jr. and Renaud M. Deraison in 2002 and is headquartered in Columbia, MD. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Howe Niloofar Razi | Director | May 28 '24 | Option Exercise | 0.00 | 3,309 | 0 | 19,170 | May 28 07:17 PM | Thurmond Mark C. | Chief Operating Officer | May 28 '24 | Sale | 43.97 | 949 | 41,728 | 32,906 | May 29 04:04 PM | Yoran Amit | President, CEO and Chairman | May 24 '24 | Sale | 43.48 | 5,684 | 247,140 | 374,922 | May 28 07:17 PM | Vintz Stephen A | Chief Financial Officer | May 24 '24 | Sale | 43.48 | 3,418 | 148,615 | 268,200 | May 28 07:17 PM | Thurmond Mark C. | Chief Operating Officer | May 24 '24 | Sale | 43.34 | 3,381 | 146,533 | 33,855 | May 28 07:17 PM |
|
|
| |
|
Market Cap | 12.06B | EPS (ttm) | 3.31 |
P/E | 52.09 | EPS this Y | 5.21% |
Forward P/E | 46.01 | EPS next Y | 21.04% |
PEG | 3.50 | EPS past 5Y | 122.47% |
P/S | 6.78 | EPS next 5Y | 14.90% |
P/B | 15.25 | EPS Q/Q | 116.08% |
Dividend | - | Sales Q/Q | 23.35% |
Insider Own | 0.85% | Inst Own | 100.89% |
Insider Trans | -2.45% | Inst Trans | -0.62% |
Short Float | 6.14% | Earnings | May 09/a |
Analyst Recom | 1.42 | Target Price | 232.62 |
Avg Volume | 875.05K | 52W Range | 125.82 - 298.95 |
|
|
|
Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Scannell Timothy J | Director | May 28 '24 | Option Exercise | 32.33 | 18,267 | 590,595 | 45,886 | May 29 04:04 PM | Scannell Timothy J | Director | May 28 '24 | Sale | 180.90 | 3,300 | 596,970 | 42,586 | May 29 04:04 PM | Petrovic Shacey | Director | Feb 28 '24 | Option Exercise | 92.11 | 11,609 | 1,069,305 | 14,176 | Feb 29 04:37 PM | Petrovic Shacey | Director | Feb 28 '24 | Sale | 162.92 | 11,609 | 1,891,338 | 2,567 | Feb 29 04:37 PM | BORIO LUCIANA | Director | Dec 15 '23 | Sale | 207.08 | 72 | 14,910 | 2,278 | Dec 18 04:01 PM |
|
|
|
|
Market Cap | 34.78B | EPS (ttm) | 17.74 |
P/E | 10.99 | EPS this Y | 5.20% |
Forward P/E | 9.21 | EPS next Y | 11.75% |
PEG | 2.07 | EPS past 5Y | 16.56% |
P/S | 3.99 | EPS next 5Y | 5.30% |
P/B | 2.05 | EPS Q/Q | 10.04% |
Dividend | 4.59% | Sales Q/Q | 15.69% |
Insider Own | 0.52% | Inst Own | 91.58% |
Insider Trans | -14.92% | Inst Trans | -0.34% |
Short Float | 2.85% | Earnings | Apr 30/a |
Analyst Recom | 1.54 | Target Price | 225.96 |
Avg Volume | 1.44M | 52W Range | 119.38 - 210.83 |
|
|
|
Diamondback Energy, Inc. is an independent oil and natural gas company, which engages in the acquisition, development, exploration, and exploitation of unconventional, onshore oil, and natural gas reserves. It operates through the Upstream and Midstream Services segments. The Upstream segment focuses on the Permian Basin operations in West Texas. The Midstream Services segment is involved in the Midland and Delaware Basins. The company was founded in December 2007 and is headquartered in Midland, TX. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Wesson Daniel N | Exec. VP & COO | May 28 '24 | Sale | 197.14 | 6,000 | 1,182,844 | 69,677 | May 29 04:02 PM | Zmigrosky Matt | EVP, Chief Legal and Admin Off | May 17 '24 | Sale | 198.15 | 6,000 | 1,188,884 | 38,445 | May 20 04:14 PM | Van't Hof Matthew Kaes | President & CFO | May 16 '24 | Sale | 195.69 | 25,000 | 4,892,312 | 160,882 | May 20 04:13 PM | Thompson Jere W III | Exec. VP - Strategy & Corp Dev | May 03 '24 | Sale | 199.90 | 900 | 179,910 | 7,585 | May 07 04:06 PM | Stice Travis D. | Chief Executive Officer | Apr 02 '24 | Sale | 200.00 | 30,000 | 6,000,060 | 446,610 | Apr 04 04:34 PM |
|
|
|
|
Market Cap | 106.48B | EPS (ttm) | 33.85 |
P/E | 28.55 | EPS this Y | 0.73% |
Forward P/E | 20.44 | EPS next Y | 7.20% |
PEG | 2.88 | EPS past 5Y | 10.31% |
P/S | 8.13 | EPS next 5Y | 9.90% |
P/B | 3.95 | EPS Q/Q | -12.56% |
Dividend | - | Sales Q/Q | -0.54% |
Insider Own | 3.63% | Inst Own | 85.57% |
Insider Trans | -6.02% | Inst Trans | -0.34% |
Short Float | 1.53% | Earnings | May 02/b |
Analyst Recom | 1.86 | Target Price | 1060.27 |
Avg Volume | 440.30K | 52W Range | 684.80 - 998.33 |
|
|
|
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
BROWN MICHAEL S | Director | May 28 '24 | Option Exercise | 625.60 | 1,172 | 733,203 | 2,554 | May 29 04:01 PM | BROWN MICHAEL S | Director | May 28 '24 | Sale | 974.86 | 1,172 | 1,142,536 | 1,382 | May 29 04:01 PM | LAROSA JOSEPH J | EVP General Counsel and Secret | May 21 '24 | Sale | 994.90 | 1,865 | 1,855,488 | 34,678 | May 22 04:02 PM | SCHLEIFER LEONARD S | Bd. Co-Chair, President & CEO | May 17 '24 | Sale | 979.23 | 22,830 | 22,355,714 | 466,877 | May 17 05:57 PM | YANCOPOULOS GEORGE | Bd. Co-Chair, President & CSO | May 16 '24 | Sale | 972.73 | 50,000 | 48,636,545 | 786,383 | May 17 04:06 PM |
|
|
|